ストックスクリーナーアプリを入手
165.70
0.27%
-0.47
前日終値:
$166.17
開ける：
$167.57
24時間の取引高:
654.14K
Relative Volume:
0.35
時価総額：
$315.91B
収益：
$54.72B
当期純損益:
$14.02B
株価収益率:
23.06
EPS:
7.1855
ネットキャッシュフロー:
$15.32B
1週間 パフォーマンス:
+3.54%
1か月 パフォーマンス:
+14.81%
6か月 パフォーマンス:
+33.63%
1年 パフォーマンス:
+55.45%
1日の値動き範囲:
$165.54
$167.86
1週間の範囲:
$159.47
$167.86
52週間の値動き範囲:
$97.72
$167.86
Novartis Ag Adr Stock (NVS) Company Profile
Compare NVS vs LLY, JNJ, ABBV, AZN
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
NVS
Novartis Ag Adr
|
165.56 | 317.08B | 54.72B | 14.02B | 15.32B | 7.1855 |
|
LLY
Lilly Eli Co
|
1,019.50 | 977.37B | 65.18B | 20.64B | 5.96B | 22.59 |
|
JNJ
Johnson Johnson
|
243.95 | 586.40B | 94.19B | 26.80B | 19.70B | 11.05 |
|
ABBV
Abbvie Inc
|
227.09 | 411.55B | 61.16B | 4.20B | 19.68B | 2.3671 |
|
AZN
Astrazeneca Plc
|
211.35 | 324.75B | 58.80B | 10.24B | 8.98B | 3.2788 |
Novartis Ag Adr Stock (NVS) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-01-27 | 開始されました | Citigroup | Buy |
| 2026-01-06 | アップグレード | Barclays | Underweight → Equal Weight |
| 2025-12-08 | アップグレード | JP Morgan | Neutral → Overweight |
| 2025-12-03 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2025-11-25 | アップグレード | BofA Securities | Neutral → Buy |
| 2025-09-12 | ダウングレード | Goldman | Neutral → Sell |
| 2025-08-08 | アップグレード | Morgan Stanley | Underweight → Equal-Weight |
| 2025-02-13 | ダウングレード | UBS | Buy → Neutral |
| 2025-02-12 | 開始されました | Morgan Stanley | Underweight |
| 2025-02-04 | アップグレード | Deutsche Bank | Hold → Buy |
| 2024-12-04 | ダウングレード | HSBC Securities | Hold → Reduce |
| 2024-09-11 | ダウングレード | BofA Securities | Buy → Neutral |
| 2024-09-05 | ダウングレード | Goldman | Buy → Neutral |
| 2024-09-03 | ダウングレード | Jefferies | Buy → Hold |
| 2024-07-19 | ダウングレード | Deutsche Bank | Buy → Hold |
| 2024-05-30 | 開始されました | Goldman | Buy |
| 2024-02-23 | 開始されました | BMO Capital Markets | Market Perform |
| 2024-01-23 | 開始されました | Morgan Stanley | Equal-Weight |
| 2024-01-16 | 再開されました | UBS | Buy |
| 2023-12-18 | ダウングレード | HSBC Securities | Buy → Hold |
| 2023-09-25 | アップグレード | Morgan Stanley | Underweight → Equal-Weight |
| 2023-07-14 | 開始されました | HSBC Securities | Buy |
| 2023-04-26 | アップグレード | Deutsche Bank | Hold → Buy |
| 2023-03-27 | アップグレード | Deutsche Bank | Sell → Hold |
| 2023-01-26 | ダウングレード | Citigroup | Buy → Neutral |
| 2022-12-05 | アップグレード | Stifel | Hold → Buy |
| 2022-09-15 | ダウングレード | Credit Suisse | Neutral → Underperform |
| 2022-09-14 | ダウングレード | Berenberg | Buy → Hold |
| 2022-05-09 | ダウングレード | Wolfe Research | Outperform → Peer Perform |
| 2022-01-10 | 再開されました | Citigroup | Buy |
| 2021-12-14 | ダウングレード | Redburn | Buy → Neutral |
| 2021-12-06 | ダウングレード | Exane BNP Paribas | Outperform → Neutral |
| 2021-12-03 | ダウングレード | Bryan Garnier | Buy → Neutral |
| 2021-09-20 | ダウングレード | Deutsche Bank | Hold → Sell |
| 2021-03-22 | 開始されました | Bernstein | Mkt Perform |
| 2021-03-10 | ダウングレード | Argus | Buy → Hold |
| 2021-02-01 | ダウングレード | Cowen | Outperform → Market Perform |
| 2021-01-15 | 開始されました | Deutsche Bank | Buy |
| 2020-09-29 | 開始されました | Berenberg | Buy |
| 2020-09-10 | アップグレード | UBS | Neutral → Buy |
| 2020-09-01 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2020-06-15 | アップグレード | Citigroup | Neutral → Buy |
| 2020-03-10 | アップグレード | Morgan Stanley | Underweight → Equal-Weight |
| 2020-02-25 | ダウングレード | Guggenheim | Buy → Neutral |
| 2019-04-25 | アップグレード | Guggenheim | Neutral → Buy |
| 2019-04-25 | アップグレード | Liberum | Hold → Buy |
| 2019-04-10 | ダウングレード | Morgan Stanley | Equal-Weight → Underweight |
| 2019-01-02 | ダウングレード | JP Morgan | Neutral → Underweight |
| 2018-12-11 | 再開されました | Jefferies | Buy |
| 2018-10-09 | 開始されました | Guggenheim | Neutral |
| 2018-09-10 | アップグレード | BofA/Merrill | Underperform → Buy |
| 2018-05-29 | ダウングレード | HSBC Securities | Buy → Hold |
| 2018-05-25 | アップグレード | Credit Suisse | Underperform → Neutral |
| 2018-01-25 | 繰り返されました | Leerink Partners | Outperform |
| 2017-12-06 | ダウングレード | BofA/Merrill | Neutral → Underperform |
| 2017-07-26 | アップグレード | Morgan Stanley | Underweight → Overweight |
| 2017-07-05 | ダウングレード | Credit Suisse | Neutral → Underperform |
| 2017-03-09 | 開始されました | Liberum | Buy |
すべてを表示
Novartis Ag Adr (NVS) 最新ニュース
Turner Syndrome Market Size to Reach USD 3.67 Billion by 2033, Fueled by Early Diagnosis Advances and Rising Awareness of Rare Chromosomal Disorders – SNS Insider - GlobeNewswire Inc.
Novartis AG stock reaches all-time high at 160.21 USD - Investing.com Nigeria
Novartis AG stock reaches all-time high at 160.21 USD By Investing.com - Investing.com South Africa
IgA Nephropathy Pipeline 2025: FDA Updates, Therapy Innovations, and Clinical Trial Landscape Analysis by DelveInsight | Visterra, Chinook Therapeutics, Novartis, IgA proteases Selecta Biosciences - Barchart.com
Novartis ADR earnings beat by $0.06, revenue fell short of estimates - Investing.com Nigeria
Novartis Faces Biggest Patent Expiry Ever but Sees Growth Ahead - Sahm
Novartis' Strong Innovation Supports Industry-Leading Margins - Morningstar
Novartis stock hits all-time high at 153.83 USD By Investing.com - Investing.com Australia
Novartis Beats on Q4 Earnings, Entresto Generics Pressure Sales - Finviz
Novartis stock hits all-time high at 153.83 USD - Investing.com
Earnings call transcript: Novartis Q4 2025 earnings beat forecasts, stock jumps - Investing.com
Peering Into Novartis AG's Recent Short Interest - Sahm
Avalo Therapeutics Stock Has More Than 200% Upside? Analyst Breaks Down Bull And Bear Case - Sahm
Why Analysts Are Closely Watching Novartis AG (NVS) - Finviz
Jim Cramer is Optimistic About Novartis' (NVS) Cancer Drug - Finviz
Novartis Shares Test 12-Month Highs on Bullish New Outlook - AskTraders.com
Corticosteroids Market Report 2026 - GlobeNewswire Inc.
Novartis Positions US Strategy As Defense Against Rising Trade Levies - Sahm
Novartis stock hits all-time high at $146.4 By Investing.com - Investing.com South Africa
Novartis stock hits all-time high at $146.4 - Investing.com
Novartis AG-Sponsored ADR (NYSE:NVS): A Quality Dividend Stock Backed by Strong Fundamentals - Chartmill
Oncolytic Virotherapy Market - GlobeNewswire Inc.
Novartis ADR: Defensive Giant Tests Investor Patience As Rally Cools - AD HOC NEWS
Novartis AG-Sponsored ADR (NYSE:NVS) Presents a Compelling Value Investment Case - Chartmill
Novartis AG (NVS) Advances $23B U.S. Investment Plan With New RLT Logistics Hub - Finviz
The Truth About Novartis AG (ADR): Why Everyone Is Suddenly Watching This Pharma Giant - AD HOC NEWS
Is Novartis AG Gaining or Losing Market Support? - Sahm
3 Dividend Stocks to Buy in 2026 and Hold Forever - Finviz
Enliven Therapeutics Early Leukemia Drug Results Impress, Stock Soars - Sahm
New Investors: 3 Stocks to Build Your Portfolio Around in 2026 - Finviz
The Truth About Novartis AG (ADR): Is Wall Street’s Quiet Giant Your Next Power Play? - AD HOC NEWS
The Truth About Novartis AG: Is This Pharma Giant a Silent Stock Cheat Code? - AD HOC NEWS
Novartis AG (ADR): Quiet Confidence Or Complacency? A Deep Look At NVS After A Steady Climb - AD HOC NEWS
Novartis AG (NYSE:NVS) Stands Out as a Dependable Dividend Stock with Strong Fundamentals - ChartMill
7 Newly Overvalued Stocks this Week - Morningstar
EBITDA per share of Novartis AG ADR Cert Deposito Arg Repr 0.25 ADRs – BCBA:NVSC - TradingView — Track All Markets
Novartis Ag Adr (NVS) 財務データ
収益
当期純利益
現金流量
EPS
3.14%
0.60%
大文字化:
|
ボリューム (24 時間):